PL2330131T3 - Przeciwciała przeciwko CTF-611, skróconemu wariantowi HER2 - Google Patents

Przeciwciała przeciwko CTF-611, skróconemu wariantowi HER2

Info

Publication number
PL2330131T3
PL2330131T3 PL09380183T PL09380183T PL2330131T3 PL 2330131 T3 PL2330131 T3 PL 2330131T3 PL 09380183 T PL09380183 T PL 09380183T PL 09380183 T PL09380183 T PL 09380183T PL 2330131 T3 PL2330131 T3 PL 2330131T3
Authority
PL
Poland
Prior art keywords
ctf
antibodies against
against her2
truncated variant
her2 truncated
Prior art date
Application number
PL09380183T
Other languages
English (en)
Inventor
López Joaquín Arribas
Kim Pedersen
Pier-Davide Angellini
Palau Josep Lluís Parra
Torres José Baselga
Original Assignee
Fundacio Privada Inst Catalana De Recerca I Estudis Avancants
Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Inst Catalana De Recerca I Estudis Avancants, Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron filed Critical Fundacio Privada Inst Catalana De Recerca I Estudis Avancants
Publication of PL2330131T3 publication Critical patent/PL2330131T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
PL09380183T 2009-12-07 2009-12-07 Przeciwciała przeciwko CTF-611, skróconemu wariantowi HER2 PL2330131T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09380183.5A EP2330131B1 (en) 2009-12-07 2009-12-07 Antibodies against HER2 truncated variant CTF-611

Publications (1)

Publication Number Publication Date
PL2330131T3 true PL2330131T3 (pl) 2015-05-29

Family

ID=42077878

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09380183T PL2330131T3 (pl) 2009-12-07 2009-12-07 Przeciwciała przeciwko CTF-611, skróconemu wariantowi HER2

Country Status (11)

Country Link
US (1) US8741586B2 (pl)
EP (3) EP2330131B1 (pl)
JP (1) JP5852306B2 (pl)
CY (1) CY1115927T1 (pl)
DK (1) DK2330131T3 (pl)
ES (2) ES2527143T3 (pl)
HR (1) HRP20141257T1 (pl)
PL (1) PL2330131T3 (pl)
PT (1) PT2330131E (pl)
SI (1) SI2330131T1 (pl)
SM (1) SMT201500001B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10416162B2 (en) 2007-12-20 2019-09-17 Monogram Biosciences, Inc. Her2 diagnostic methods
WO2010065568A2 (en) 2008-12-01 2010-06-10 Laboratory Corporation Of America Holdings METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
CA2761777A1 (en) * 2009-05-14 2010-11-18 Prometheus Laboratories Inc. Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
EP2797628A4 (en) 2011-12-27 2015-07-29 Kadmon Corp Llc METHODS OF TREATING BREAST CANCER NOT RESPONDING TO TRASTUZUMAB
JP6510532B2 (ja) * 2013-12-20 2019-05-08 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性ｈｅｒ２抗体及び使用方法
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
EP3519437B1 (en) * 2016-09-30 2021-09-08 F. Hoffmann-La Roche AG Bispecific antibodies against p95her2
US20200088731A1 (en) * 2016-12-22 2020-03-19 Hitachi Chemical Company, Ltd. Method for Detecting HER2-Positive Cancer Cells
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
WO2019116089A2 (en) * 2017-12-11 2019-06-20 Medizinische Universitaet Wien A method of producing a vaccine composition and uses thereof
CN110865184B (zh) * 2019-12-04 2023-04-07 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） Srsp蛋白和srsp抗原表位肽的应用及诊断和***的产品
EP3915576A1 (en) 2020-05-28 2021-12-01 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Chimeric antigen receptors specific for p95her2 and uses thereof
JP7393774B2 (ja) 2020-11-30 2023-12-07 小野薬品工業株式会社 Ｈｅｒ２標的化剤
WO2023143322A1 (zh) * 2022-01-26 2023-08-03 山东先声生物制药有限公司 p95HER2抗体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
ES2342646B1 (es) * 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
WO2010065568A2 (en) * 2008-12-01 2010-06-10 Laboratory Corporation Of America Holdings METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95

Also Published As

Publication number Publication date
DK2330131T3 (da) 2015-01-05
US20110135653A1 (en) 2011-06-09
SI2330131T1 (sl) 2015-02-27
ES2527143T3 (es) 2015-01-20
JP5852306B2 (ja) 2016-02-03
EP3048117A1 (en) 2016-07-27
SMT201500001B (it) 2015-03-05
CY1115927T1 (el) 2017-01-25
EP2330131A1 (en) 2011-06-08
EP2330131B1 (en) 2014-10-08
PT2330131E (pt) 2015-01-14
ES2581627T3 (es) 2016-09-06
EP2360187A1 (en) 2011-08-24
EP2360187B1 (en) 2016-04-20
US8741586B2 (en) 2014-06-03
JP2011121943A (ja) 2011-06-23
HRP20141257T1 (en) 2015-03-13

Similar Documents

Publication Publication Date Title
HRP20141257T1 (en) Antibodies against her2 truncated variant ctf-611
IL214996A0 (en) Anti-bcma antibodies
GB0920127D0 (en) Antibodies
EP2409990A4 (en) VARIANT OF A CONSTANT ANTIBODY REGION
EP2409991A4 (en) VARIANT OF A CONSTANT REGION OF ANTIBODIES
GB0909906D0 (en) Antibodies
ZA201104545B (en) Anti-siglec-15 antibody
EP2427496A4 (en) ANTI-VEGF-D ANTIBODIES
EP2481752A4 (en) MODIFIED CONSTANT ANTIBODY REGIONS
SG10201404019XA (en) Muc1 antibodies
IL217919A0 (en) Humanized anti-cdcp1 antibodies
GB0821100D0 (en) Antibodies
HK1168871A1 (zh) 單克隆抗體
EP2337798A4 (en) BSA-SPECIFIC ANTIBODIES
GB0920324D0 (en) Antibodies
ZA201006099B (en) Anti-tyrp1 antibodies
EP2426149A4 (en) ANTI-CADHERIN ANTIBODY
HK1170745A1 (en) Antibodies against il-17br il-17br
ZA201007976B (en) Anti-pirb antibodies
EP2400984A4 (en) HER2 ANTIBODY COMPOSITIONS
GB0818356D0 (en) Antibodies
GB2473934B (en) Anti-VEEV antibody
EP2499256A4 (en) ANTI-C-MPL ANTIBODIES
EP2511371A4 (en) PEPTIDANT BODY AGAINST CANCER AND MORTALINE
EP2424892A4 (en) DC-STAMP ANTIBODY